“…Treatment of HCV with cyclophilin inhibitors has been very promising however. Three compounds, NIM811 ( 7 , Figure ), alisporivir ( 8 , Figure ), SCY-635 ( 9 , Figure ), have been investigated in clinical trials, and each has demonstrated therapeutic efficacy . Several cyclophilins contribute to the HCV viral life cycle, , and strong evidence indicates that cyclophilin A interacts with the viral NS5A protein to stimulate the replication of the RNA genome. , In contrast to most direct antivirals, significant resistance to cyclophilin inhibitors is rarely observed, and cyclophilin inhibitors are potent across all HCV genotypes. , …”